November 23, 2016 7:26am
… Little volume, a thinning field, speculative sentiment, depreciating indexes and ETFs and a sector with focus elsewhere …
Re stocks, I’d be looking to play “pick-up-stocks”
I answer one question; in which company should investors put, keep and commit their money!
If you are not a subscriber, you won’t know the morning’s indications and who is in the headlights.
I write in every line that investors need to avoid risks as if I were the first to be hurt if I am wrong!
RegMed Investors’ (RMi) provides exclusive and original content; put your eyes on the page to figure out what’s really going on!
I keep track of closes, indexes and pricing as news lately lacks any energy as the social media impact of RMi reporting stimulates the reality of “our” universe as well as disrupting element in the trading of sector equities!
BUY: AGTC, FATE
SELL: IMUC, KOOL, OPXA
Indexes and ETFs: The IBB (-1.78%), XLV (-0.64%) ,IWM (-0.14%) and XBI (-0.31%) are DOWN
Dow futures are DOWN -0.02% and NASDAQ futures are DOWN -0.11%
U.S. stock index futures pointed to a lower open on Wednesday ahead of a Thanksgiving holiday as Wall Street hit record highs …
European stocks were trading slightly lower, following new record highs on Wall Street, as investors focused on new economic data and an upcoming budget announcement in the U.K.
Asia Pacific markets posted smaller gains or slim declines as attention remained on prospects to sustain record gains in the U.S. while Australian stocks gained smartly on expectations of higher commodity prices.
Data docket: will see jobless claims and durable goods orders released at 8:30 a.m. ET. A little later in the morning at 9:45 a.m. ET, flash Markit PMI is set to be released and new home sales and consumer sentiment for October and November respectively will be released at 10 a.m. ET.
The stem, cell, gene and regenerative therapy (SCG&RT) sector closed NEGATIVE on Tuesday, POSITIVE on Monday, Friday and Thursday and NEGATIVE last Wednesday.
The SCG&RT sector’s record after the last 5 days (of 43 covered companies):
· Tuesday closed NEGATIVE with 26 decliners, 14 advancers and 3 flats;
· Monday closed POSITIVE with 15 decliners, 27 advancers and 1 flat;
· Friday closed POSITIVE with 17 decliners, 24 advancers and 2 flats;
· Thursday closed POSITIVE with 15 decliners, 28 advancers and 0 flats;
· Last Wednesday closed NEGATIVE with 26 decliners, 13 advancers and 4 flats;
Remembering Tuesday’s closing investor letter, “Binge and bolt … The sector opened positive, fell off the cliff at 10:30 am, kept going down at the mid-day and closed depressed. The iShares Russell 2000 (IWM) indicated a positive pre- open of +0.36% and closed UP +0.91% while the iShares NASDAQ Biotechnology (IBB) indicate a pre-open positive +0.17% and closed DOWN -1.87%.”
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
· The iShares Nasdaq Biotechnology (IBB) closed Tuesday down -1.87% and is DOWN -1.78% in Wednesday’s pre-market;
· The SPDR S&P Biotech ETF (XBI) closed Tuesday down -2.61% and is DOWN -0.31% in Wednesday pre-market;
· The Health Care Select Sector SPDR ETF (XLV) closed down -1.44% Tuesday and is DOWN -0.64% in Wednesday’s pre-market;
· The iShares Russell 2000 (IWM) closed up +1.20% on Tuesday and is DOWN -0.14% in Wednesday’s pre-market.
Companies in my headlights:
Applied Genetic Technologies (AGTC) closed DOWN -$0.25 to $9.70. Up, down, up, down – it’s like a drill sergent is calling cadence to those retail recruits. There is still $9.23 of cash in the per share pricing, revenue, net income and a solid partner – Biogen (BIIB) - BUY;
Cesca Therapeutics (KOOL) closed UP +$0.22 to $3.21. After a few days of retail brokers climbing the beanstock of appreciation; they ususlly reach a thorny branch – post Monday’s $2.99 - SELL;
ImmunoCellular (NYSEMKT: IMUC) closed DOWN -$0.11 to $3.19 following Monday’s +4938.17% to $3.30 (+$3.235) post Friday’s $0.065 (-$0.0046). IMUC common stock and listed warrants began trading Monday on the NYSE MKT on a split-adjusted basis – a one-for-forty reverse stock split. Concurrently, the authorized number of shares of IMUC's common stock will be reduced from 249 M to 25 M. Watch for the historical downside movement post a reverse … Maintaining SELL;
Fate Therapeutics (FATE) closed UP +$0.28 to $2.94. FATE just raised approximately $57 M prior to ordinary fees and associated expenses while news resounded about the EU granted FATE Orphan Drug designation on 11/18/16 for its treatment in haematopoietic stem cell transplantation with FATE trading over 1.47 million shares on Tuesday. With cash in the bank, an Orphan Designation and closing a strong financing deal, FATE) appears to be on track to deliver some meaningful data in the coming months – BUY;
Opexa (OPXA) closed DOWN -$0.42 to $1.05 following Monday’s $1.47 (+$0.80). The jump from $0.67 <Friday>, $0.55 <Thursday>, $0.55 <Wednesday’s $0.59, Tuesday and Monday’s $0.56 – it’s a turkey. The aftermarket indication is negative -$0.02 – Maintaining SELL;
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.
